Stocksigma LogoStocksigma Logo

Medicamen Biotech Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh)

■ Revenue: 5,483 (+16.2% YoY | +14.5% QoQ) ■ EBITDA: 869 (+68.5% YoY | +100.8% QoQ) ■ EBITDA Margin (%): 15.8 (+491 bps YoY | +681 bps QoQ) ■ PAT: 341

Medicamen Biotech Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh)

Medicamen Biotech Ltd · Outcome · 13 Nov 2026, 9:43 pm

Medicamen Biotech Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh) ■ Revenue: 5,483 (+16.2% YoY | +14.5% QoQ) ■ EBITDA: 869 (+68.5% YoY | +100.8% QoQ) ■ EBITDA Margin (%): 15.8 (+491 bps YoY | +681 bps QoQ) ■ PAT: 341 (+27.9% YoY | +61.0% QoQ) ■ EPS (INR): 3.04 (+94.9% YoY | +123.5% QoQ)

Original exchange filing (PDF)

More announcements from Medicamen Biotech Ltd

All Medicamen Biotech Ltd announcements